12/16
08:28 am
edit
Rating for EDIT
Low
Report
Rating for EDIT
12/16
08:22 am
edit
Rating for EDIT
Low
Report
Rating for EDIT
12/16
07:05 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
12/16
06:16 am
edit
Editas Medicine downgraded to Underweight from Neutral at JPMorgan
Low
Report
Editas Medicine downgraded to Underweight from Neutral at JPMorgan
12/13
12:25 pm
edit
Rating for EDIT
Medium
Report
Rating for EDIT
12/13
12:25 pm
edit
Rating for EDIT
Medium
Report
Rating for EDIT
12/13
09:56 am
edit
Rating for EDIT
Medium
Report
Rating for EDIT
12/13
09:56 am
edit
Rating for EDIT
Medium
Report
Rating for EDIT
12/13
09:24 am
edit
Rating for EDIT
High
Report
Rating for EDIT
12/13
09:03 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its "neutral" rating re-affirmed by analysts at Chardan Capital.
High
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its "neutral" rating re-affirmed by analysts at Chardan Capital.
12/13
08:03 am
edit
Editas Medicine downgraded to Neutral from Buy at Chardan
High
Report
Editas Medicine downgraded to Neutral from Buy at Chardan
12/13
07:54 am
edit
Rating for EDIT
High
Report
Rating for EDIT
12/13
07:54 am
edit
Rating for EDIT
High
Report
Rating for EDIT
12/13
07:40 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $3.00 price target on the stock, down previously from $11.00.
High
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $3.00 price target on the stock, down previously from $11.00.
12/13
07:40 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $3.00 price target on the stock, down previously from $11.00.
High
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $3.00 price target on the stock, down previously from $11.00.
12/13
04:35 am
edit
Rating for EDIT
High
Report
Rating for EDIT
12/12
08:04 pm
edit
Editas Medicine downgraded to Hold from Buy at Stifel
High
Report
Editas Medicine downgraded to Hold from Buy at Stifel
12/11
08:21 am
edit
Rating for EDIT
Medium
Report
Rating for EDIT
12/11
08:21 am
edit
Rating for EDIT
Medium
Report
Rating for EDIT
12/11
08:08 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $4.00 price target on the stock, down previously from $7.00.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $4.00 price target on the stock, down previously from $7.00.
12/11
05:51 am
edit
Editas Medicine downgraded to Equal Weight from Overweight at Wells Fargo
Medium
Report
Editas Medicine downgraded to Equal Weight from Overweight at Wells Fargo
12/11
05:51 am
edit
Editas Medicine downgraded to Equal Weight from Overweight at Wells Fargo
Medium
Report
Editas Medicine downgraded to Equal Weight from Overweight at Wells Fargo
11/6
01:02 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.
11/6
01:02 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.
11/5
05:34 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.